PRAMOMOLECULAR Revenue

About PRAMOMOLECULAR

PRAMOMOLECULAR develops self-delivering siRNAs. Our therapeutic oligonucleotides can downregulate mRNAs in lung, pancreas, heart and colon. We are thus developing drug candidates to causally cure serious cancers such as lung, colon or pancreatic carcinoma or metabolic diseases, e.g. of the heart - as in Noonan syndrome. Currently, we are working on our preclinical in vivo proof of concept experiments. A special feature of our technology is that we couple defined lipid residues directly to siRNAs via defined chemical bonds. This gives us one of the simplest, patent-protected platform technologies for introducing therapeutic oligonucleotides into organs besides the liver in vivo. This is of great therapeutic importance, as delivery of siRNAs has previously only worked in local applications, such as in the eye or muscle, or systemically in the liver. We are also providing siRNA based drug candidates for selected other organs. PRAMOMOLECULAR is financially supported by the European Union from the Operational Program EFRE Berlin 2027 and by the State of Berlin. Within the scope of the project funding, we intend to provide disease-specific drug candidates to address overexpressed or mutated RAS proteins. Misregulated RAS proteins can lead to severe metabolic diseases or cancer. We initially want to address KRAS-dependent cancers, one of the most common RAS mutations, which can lead to non-small cell lung cancer, pancreatic adenocarcinoma or melanoma. The goal of the funded project is the provision of well-tolerated and effective therapeutics for patients suffering from non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).

View contact profiles from PRAMOMOLECULAR